

MEDICAMEN Biotech Limited



Regd. & Corp. Office:
1506, Chiranjiv Tower,
43, Nehru Place,
New Delhi - 110019 (INDIA)

Tel.: 011 - 47589500-51 (50 Lines),
E-mail: info@medicamen.com
Web: www.medicamen.com
CIN No.:
L74899DL1999PLC056594

Ref: STEX/Results/Published-2020-21

Date: 16th February, 2021

The BSE Ltd.
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai- 400001

Company Number: 531146

**Sub. : Copy of Publication of Un-audited Financial Results (Standalone & Consolidated)
for the Quarter and Nine months ended on 31st December, 2020**

Dear Sir,



Pursuant to Regulation 47 of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the copies of newspaper publication pertaining to the Un-Audited Financial Results (Standalone & Consolidated) for the Quarter and Nine months ended on 31st December, 2020, published in Financial Express (English) and Jansatta (Hindi) newspaper on 13.02.2021.

This is for your information and records.

Kindly acknowledge the receipt.

Thanking You,

Yours truly,
For Medicamen Biotech Limited



Parul Choudhary
Company Secretary
ACS44157

Encl: As above.



MEDICAMEN BIOTECH LTD.

Regd. Office: 1506, Chiranjiv Tower, 43, Nehru Place, New Delhi-110019
CIN : L74899DL 1993PLC056594 E-mail : cs@medicamen.com, www.medicamen.com

Extracts of Standalone and Consolidated Un-audited Financial Results for the Quarter & Nine months ended on 31.12.2020 (In Lakhs)

Sl. No.	Particulars	Standalone					Consolidated				
		Quarter Ended		Nine months ended		Year Ended	Quarter Ended		Nine months ended		Year Ended
		Un-audited 31.12.2020	Un-audited 31.12.2019	Un-audited 31.12.2020	Un-audited 31.12.2019	Audited 31.03.2020	Un-audited 31.12.2020	Un-audited 31.12.2019	Un-audited 31.12.2020	Un-audited 31.12.2019	Audited 31.03.2020
1	Total income from operations (net)	3292.28	3578.56	9002.59	10282.11	11925.09	3292.28	3578.56	9169.41	10282.11	12744.26
2	Net Profit/ (Loss) for the period (before tax, exceptional and/ or Extraordinary items)	445.48	505.83	1210.77	1459.52	1660.39	445.48	505.83	1229.33	1459.52	1798.02
3	Net Profit/ (Loss) for the period before tax (after exceptional and/ or Extraordinary items)	445.48	505.83	1210.77	1459.52	1660.39	445.48	505.83	1229.33	1459.52	1798.02
4	Net Profit/ (Loss) for the period after tax (after exceptional and/ or Extraordinary items)	301.47	367.94	834.31	1079.78	1225.89	301.47	367.94	848.25	1079.78	1329.12
5	Total comprehensive income for the period (Comprising Profit/ (loss) for the period (after tax) and other Comprehensive income (after tax))	301.47	367.94	834.31	1079.78	1225.89	301.47	367.94	848.25	1079.78	1329.12
6	Equity Share Capital	1221.66	1221.66	1221.66	1221.66	1221.66	1221.66	1221.66	1221.66	1221.66	1221.66
7	Reserves (excluding Revaluation Reserve as shown in the Balance Sheet of previous year)										
8	Earnings Per Share (of Rs.10/- each) (for continuing and discontinued operation)										
	Basic:	2.47	3.05	6.83	8.94	10.09	2.47	3.05	6.94	8.94	10.94
	Diluted:	2.47	3.05	6.83	8.94	10.09	2.47	3.05	6.94	8.94	10.94

Note:

- The above results after being reviewed by the Audit Committee have been taken on record by the Board at its Meeting held on 12th February'2021
- This statement has been prepared in accordance with the Companies (Indian Accounting Standard) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.
- The company operates only in one business segment, viz. Pharmaceuticals formulations, hence segment reporting is not applicable
- The Earning Per Share has been calculated as per Indian Accounting Standard (Ind AS) 33 - "Earning per Share"
- Limited Review Report has been carried out by the Statutory Auditors for the above period.
- Due to Covid-19, top line & bottom line have been impacted with the increase in the prices of Raw Materials during the current quarter and Nine Months Ending otherwise gross margins, EBITDA & PAT all on uptrend.
- Our state of art US FDA compliant Oncology Plant at Haridwar shall start taking plant validations of Oncology products from 24th February, 2021.
- The figures are regrouped in previous year also, wherever considered necessary, to make them comparable.

For Medicamen Biotech Limited
Sd/-
Rahul Bishnoi
Chairman

Place: New Delhi
Date : 12.02.2021

न्यू ऐरा लिजिंग एण्ड फाइनेन्स लिमिटेड

पंजीकृत कार्यालय: 981, अग्रवाल मिलेनियम, टॉवर-II, नेताजी सुभाष प्लेस, डिस्ट्रिक्ट सेन्टर, वजीरपुर, टीवी टॉवर के सामने, पीतम्पुरा, नई दिल्ली- 110034
CIN: L67120DL1984PLC018800, ई-मेल: neweraleasingfinance@gmail.com, दूरभाष: Ph: 011-69999350 Website: www.neweraleasingfinance.com

31 दिसम्बर, 2020 को समाप्त तिमाही एवं नौमाही के अनअंकेक्षित एकीकृत उद्धरित वित्तीय परिणाम

(रु० लाखों में)

क्र० सं०	विवरण	समाप्त तिमाही (अनअंकेक्षित)			समाप्त नौमाही (अनअंकेक्षित)		समाप्त वार्षिक (अंकेक्षित)
		31-12-2020	30-09-2020	31-12-2019	31-12-2020	31-12-2019	31-03-2020
1	संचालन से कुल आय	0.00	1.45	0.00	1.45	0.00	9.23
2	अवधि के लिए शुद्ध लाभ/(हानि) (कर से पहले (विशिष्ट एवं/अथवा असाधारण मदों से पूर्व))	(3.22)	(1.8700)	(1.29)	(6.29)	(3.98)	0.18
3	कर से पहले अवधि के लिए शुद्ध लाभ/(हानि) (विशिष्ट एवं/अथवा असाधारण मदों के बाद)	(3.22)	(1.8700)	(1.29)	(6.29)	(3.98)	0.18
4	कर के बाद अवधि के लिए शुद्ध लाभ/(हानि) (विशिष्ट एवं/अथवा असाधारण मदों के बाद)	(3.22)	(1.8700)	(1.29)	(6.29)	(3.98)	0.18
5	अवधि के लिए कुल व्यापक आय (अवधि के लिए लाभ/(हानि) शामिल (कर के बाद) एवं अन्य व्यापक आय (कर के बाद) (संदर्भ नोट 2)	(3.22)	(1.8700)	(1.29)	(6.29)	(3.98)	0.18
6	प्रदत्त इक्विटी शेयर पूंजी (सममूल्य रु० 10/- प्रति शेयर्स)	400.00	400.00	400.00	400.00	400.00	400.00
7	रिजर्व (रिवेन्यू सेन रिजर्व को छोड़कर) जैसा कि पिछले वर्ष के अंकेक्षित तुलन पत्र में दर्शाया गया						-44.03
8	प्रति शेयर आय (रु० 10/- प्रति शेयर्स) संचालन जारी एवं बंद करने के लिए:						
	मूलः	(0.0081)	(0.0047)	(0.0032)	(0.0157)	(0.0100)	0.0004
	तरलः	(0.0081)	(0.0047)	(0.0032)	(0.0157)	(0.0100)	0.0004



MEDICAMEN BIOTECH LTD.

Regd. Office: 1506, Chiranjiv Tower, 43, Nehru Place, New Delhi-110019
CIN : L74899DL 1993PLC056594 E-mail : cs@medicamen.com, www.medicamen.com

Extracts of Standalone and Consolidated Un-audited Financial Results for the Quarter & Nine months ended on 31.12.2020 (In Lakhs)

Sl. No.	Particulars	Standalone					Consolidated				
		Quarter Ended		Nine months ended		Year Ended	Quarter Ended		Nine months ended		Year Ended
		Un-audited 31.12.2020	Un-audited 31.12.2019	Un-audited 31.12.2020	Un-audited 31.12.2019	Audited 31.03.2020	Un-audited 31.12.2020	Un-audited 31.12.2019	Un-audited 31.12.2020	Un-audited 31.12.2019	Audited 31.03.2020
1	Total income from operations (net)	3292.28	3578.56	9002.59	10282.11	11925.09	3292.28	3578.56	9169.41	10282.11	12744.26
2	Net Profit/ (Loss) for the period (before tax, exceptional and/or Extraordinary items)	445.48	505.83	1210.77	1459.52	1660.39	445.48	505.83	1229.33	1459.52	1798.02
3	Net Profit/ (Loss) for the period before tax (after exceptional and/or Extraordinary items)	445.48	505.83	1210.77	1459.52	1660.39	445.48	505.83	1229.33	1459.52	1798.02
4	Net Profit/ (Loss) for the period after tax (after exceptional and/or Extraordinary items)	301.47	367.94	834.31	1079.78	1225.89	301.47	367.94	848.25	1079.78	1329.12
5	Total comprehensive income for the period (Comprising Profit/ (loss) for the period (after tax) and other Comprehensive income (after tax))	301.47	367.94	834.31	1079.78	1225.89	301.47	367.94	848.25	1079.78	1329.12
6	Equity Share Capital	1221.66	1221.66	1221.66	1221.66	1221.66	1221.66	1221.66	1221.66	1221.66	1221.66
7	Reserves (excluding Revaluation Reserve as shown in the Balance Sheet of previous year)										
8	Earnings Per Share (of Rs. 10/- each) (for continuing and discontinued operation)										
	Basic:	2.47	3.05	6.83	8.94	10.09	2.47	3.05	6.94	8.94	10.94
	Diluted:	2.47	3.05	6.83	8.94	10.09	2.47	3.05	6.94	8.94	10.94

Note:

- The above results after being reviewed by the Audit Committee have been taken on record by the Board at its Meeting held on 12th February 2021
- This statement has been prepared in accordance with the Companies (Indian Accounting Standard) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.
- The company operates only in one business segment, viz. Pharmaceuticals formulations, hence segment reporting is not applicable
- The Earning Per Share has been calculated as per Indian Accounting Standard (Ind AS) 33 - "Earning per Share"
- Limited Review Report has been carried out by the Statutory Auditors for the above period.
- Due to Covid-19, top line & bottom line have been impacted with the increase in the prices of Raw Materials during the current quarter and Nine Months Ending otherwise gross margins, EBITDA & PAT all on uptrend.
- Our state of art US FDA compliant Oncology Plant at Haridwar shall start taking plant validations of Oncology products from 24th February, 2021.
- The figures are regrouped in previous year also, wherever considered necessary, to make them comparable.

Place: New Delhi
Date : 12.02.2021

For Medicamen Biotech Limited
Sd/-
Rahul Bishnoi
Chairman

ICTS INTERNATIONAL CENTRE FOR THEORETICAL SCIENCES
Tata Institute of Fundamental Research
No 151, Suvakote, Hesaraghatta Hobli, Bengaluru (North)-560089, India, Tel : +91-80-46536000

TENDER NOTICE 02/FEB/2021

Sealed Tenders IN TWO BID SYSTEM (Techno - Commercial & Price Bid) are invited from reputed Contractors for the following :

Ref No.	ICTS/TIFR/2020-21/SER-29
Name of Work	Hiring of Vehicles - Scheduled and Unscheduled Cars
EMD Amt	Rs. 87,000/-
Last Date for Document Download	14/03/2021 till 17.00 Hrs
Date of Pre Bid Meeting	05/03/2021 at 11.30 Hrs
Last Date for Submission of Tender	15/03/2021 till 15.00 Hrs
Date of Opening Tender	15/03/2021 at 15.30 Hrs

The above advertisement is available on our Website - <http://www.icts.res.in/tenders> and Central Public Procurement Portal - <http://eprocure.gov.in/cppp>. The Prebid meetings will be held online. The online meeting link is given in the tender document.

Administrative Officer

Morn Media Limited
Regd. Office: Jagran Building, 2, Sarvodaya Nagar, Kanpur-208 005
CIN: L22121UP1983PLC006177 • ISIN: INE343T01016
• Tel. No.: 0512-2216161 • E-mail: mornmedialimited@hotmail.com
• Website: www.mornmedia.com

Extract of Unaudited Financial Results for the Quarter and nine months ended December 31, 2020

Particulars	(Rs. in Lakhs, except per share data)		
	Quarter Ended 31.12.2020 (Unaudited)	Nine Months Ended 31.12.2020 (Unaudited)	Quarter Ended 31.12.2019 (Unaudited)
Total income from operations			
Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	1.82	(0.84)	(0.42)
Net Profit / (Loss) for the period before Tax (after Exceptional and/or Extraordinary items)	1.82	(0.84)	(0.42)
Net Profit / (Loss) for the period after Tax (after Exceptional and/or Extraordinary items)	0.97	(0.36)	(0.16)
Total Comprehensive Income for the period (Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax))	0.97	(0.36)	(0.16)
Equity Share Capital (Face value Rs. 10 per share)	50.00	50.00	50.00
Reserves (excluding revaluation reserve)			
Earnings Per Share (Face value of Rs. 10/- each) (not annualized) (in Rs.)			
- Basic	0.20	(0.07)	(0.04)
- Diluted	0.20	(0.07)	(0.04)

Notes: